Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Journal of Primary Health Care|September 29, 2020
Ageing badly: indicators of old-age structure in Australia and New ZealandYoram Barak, Shona Neehoff, Paul GlueJournal of Psychopharmacology (Oxford, England)|September 20, 2017
Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disordersCameron Castle, Andrew Gray, Shona Neehoff, et al.Journal of Psychopharmacology (Oxford, England)|September 9, 2020
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating ScaleDylan Truppman Lattie, Hayley Nehoff, Shona Neehoff, et al.The International Journal of Neuropsychopharmacology|May 3, 2018
Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social AnxietyShabah Mohammad Shadli, Tame Kawe, Daniel Martin, et al.Journal of Psychopharmacology (Oxford, England)|January 31, 2024
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover studyPaul Glue, Shona Neehoff, Ben Beaglehole, et al.Therapeutic Advances in Psychopharmacology|June 12, 2020
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot studyPaul Glue, Natalie J Medlicott, Shona Neehoff, et al.Journal of Psychopharmacology (Oxford, England)|September 19, 2019
Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication studyPaul Glue, Shona Neehoff, Amandine Sabadel, et al.Journal of Psychopharmacology (Oxford, England)|April 27, 2017
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disordersPaul Glue, Natalie J Medlicott, Sarah Harland, et al.Journal of Psychopharmacology (Oxford, England)|November 28, 2024
Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover studyBen Beaglehole, Paul Glue, Shona Neehoff, et al.Journal of Psychopharmacology (Oxford, England)|June 5, 2025
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorderBen Beaglehole, Paul Glue, Shona Neehoff, et al.Pageof 2